EMPEROR-Preserved Benefit Stratification Index
Patient and baseline risk inputs
Estimate the potential absolute benefit of empagliflozin for the EMPEROR-Preserved primary composite endpoint.
Clinical context
EMPEROR-Preserved evaluated empagliflozin 10 mg once daily versus placebo in 5,988 patients with heart failure and LVEF greater than 40%, on top of usual therapy. The primary endpoint was cardiovascular death or hospitalization for heart failure.
| Trial outcome | Empagliflozin | Placebo |
|---|---|---|
| Primary endpoint | 13.8% | 17.1% |
| Hazard ratio (95% CI) | 0.79 (0.69–0.90) | |
| Median follow-up | 26.2 months | |
| Approximate absolute difference in observed event proportions | 3.3 percentage points | |
How this calculator works
- Uses a supplied baseline risk when entered; otherwise starts from the trial placebo event proportion and applies the original feature multipliers.
- Approximates treated cumulative risk using a proportional-hazards transformation: 1 − (1 − baseline risk)HR.
- Calculates ARR as baseline risk minus estimated treated risk and NNT as the reciprocal of ARR expressed as a proportion.
References and limitations
Anker SD, Butler J, Filippatos G, et al.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385:1451–1461.
doi:10.1056/NEJMoa2107038 · PMID: 34449189
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385:1451–1461.
doi:10.1056/NEJMoa2107038 · PMID: 34449189
Important limitations
The feature multipliers are pragmatic assumptions and have not been validated as a prognostic model. The HR-to-risk transformation is approximate and assumes proportional hazards; it does not reproduce a patient-level survival model or account for competing risks, recurrent hospitalizations, treatment adherence, or subgroup-specific effects.
The feature multipliers are pragmatic assumptions and have not been validated as a prognostic model. The HR-to-risk transformation is approximate and assumes proportional hazards; it does not reproduce a patient-level survival model or account for competing risks, recurrent hospitalizations, treatment adherence, or subgroup-specific effects.
Clinical use
Use alongside guideline recommendations, contraindications, safety assessment, patient preferences, and clinical judgment. Do not use these estimates as the sole basis for starting or withholding therapy.
Use alongside guideline recommendations, contraindications, safety assessment, patient preferences, and clinical judgment. Do not use these estimates as the sole basis for starting or withholding therapy.
PERSONAL WORKSPACE
Clinical notes
Document key findings and keep a structured record for your own reference.
Private by design. Notes are stored in this browser on this device only. They are not uploaded to Appcardio.
Export or share this note
PERSONAL WORKSPACE
My notes
Review, edit, or remove notes saved in this browser.
Stored locally on this device
QUALITY & SAFETY
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.
Please describe the issue clearly. For calculation concerns, include the input values and expected result where possible.